Product overview

Name SL 0101-1
Alternative names SL0101
Purity >95%
Description Selective p90 ribosomal S6 kinase inhibitor
Write Your Own Review
You're reviewing:SL 0101-1
Rate this item:

Biological Data

Biological description Selective p90 ribosomal S6 kinase (RSK) inhibitor (IC50 = 89 nM for RSK2). Shows anti-proliferative actions against cancer cell lines.

Solubility & Handling

Storage instructions -20°C
Solubility overview Soluble in ethanol (20mM) or DMSO (10mM)
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Purity >95%
Chemical name 3-[(3,4-Di-O-acetyl-6-deoxy-α-L-mannopyranosyl)oxy]-5,7-dihydro-2-(4-hydroxyphenyl)-4H -1benzopyran-4-one
Molecular Weight 516.46
Chemical structure SL 0101-1  [77307-50-7] Chemical Structure
Molecular Formula C25H24O12
CAS Number 77307-50-7
PubChem identifier 14825856
SMILES O=C1C3=C(C=C(O)C=C3O)OC(C4=CC=C(O)C=C4)=C1OC2C(O)C(OC(C)=O)C(OC(C)=O)C(C)O2
InChiKey SXOZSDJHGMAEGZ-UHFFFAOYSA-N

References for SL 0101-1

References are publications that support the biological activity of the product
  • Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.

    Shiota M et al (2014) Prostate 74(9) : 959-69.
  • The selectivity of protein kinase inhibitors: a further update.

    Bain J et al (2007) Biochem J 408(3) : 297-315.
  • Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.

    Smith JA et al (2005) Cancer Res 65(3) : 1027-34.

3 Item(s)